PLEASANTON, CA — April 16, 2019 — Veeva Systems (NYSE:VEEV) today announced that a top 20 pharmaceutical company has selected Veeva Vault Clinical Data Management System (CDMS) as their global standard for EDC, coding, data cleaning, and reporting.
“This is a landmark announcement for the clinical data management market,” said Henry Levy, general manager, Veeva Vault CDMS. “Veeva Vault CDMS was selected because the company wanted a modern cloud solution on a world-class platform from a partner they could trust.”
Vault CDMS provides a suite of clinical data management applications that combines coding, EDC, data cleaning, and reporting all on a single cloud platform. Companies can now manage study build through execution in an integrated way. With a complete and concurrent view of their data, clinical development teams can make better decisions faster.
As part of Vault CDMS, Veeva Vault EDC provides a fast and intuitive interface for capturing clinical trial data. Designed for flexibility, Vault EDC allows customers to run complex multi-arm adaptive trials and make mid-study amendments without downtime or migrations.
“Our goal is to become the market leader in the clinical data management market over time through innovation and product excellence,” added Levy. “We are honored to partner with this important customer and look forward to delivering customer success for many years.”
For more on Veeva Vault CDMS, visit: veeva.com/CDMS
Connect with Veeva on LinkedIn: www.linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: www.twitter.com/veevasystems
Like Veeva on Facebook: www.facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.